The announcements include:

  • Anthem Blue Cross and Blue Shield eligible members will be the first commercially insured patients in the United States to benefit from medical policy coverage supporting blood-based biomarker testing for Alzheimer’s disease.
  • Publication of new peer-reviewed study comparing LucentAD® Complete against an immunoprecipitation mass spectrometry (IP-MS) method on a shared patient cohort, demonstrating strong diagnostic parity while combining five biomarkers across amyloid pathology, tau pathology, neurodegeneration, and neuroinflammation.
    • New clinical data presented at the Alzheimer’s Association International Conference (AAIC) 2026 highlighting the role of multi-biomarker testing in supporting patient triage and supporting earlier clinical decision making.